Skip to content
Discover expert analysis, in-depth articles, and unique per…

Patients Coming Off Slimming Jabs Regain Pounds at a Quadrupled Rate Compared to Those on Conventional Diets

Image of pharmaceutical injection and scale
Obesity treatment involves long-term strategies.

A recent study suggests that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end traditional diet and exercise plans.

Findings released in a major health publication points out that while overweight individuals frequently drop about a fifth of their body weight while using the jabs, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing these treatments should be cognizant of the potential of quick weight regain when the treatment ends," warns expert Dr. Susan Jebb.

That rate of regain means a reversion to pre-treatment mass within about 18 months.

Comparing Therapies

The analysis, which examined dozens of trials involving thousands of patients, compared the outcomes of the injectable medications with older methods.

Scientists note that individuals who lose weight through dieting generally experience a more gradual weight regain—approximately 100 grams monthly—after stopping.

The Reason for the Quick Regain

Doctors believe the mechanism of the jabs explains the amplified rebound.

GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger.

"Sustained high doses of the hormone concentrations several times higher than normal might result in the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.

"Stopping of this hormone supplement results in hunger is no longer kept in check, making excessive eating far more likely."

An Ongoing Disease?

The NHS recommend the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.

Professionals say that, considering the significant potential of relapse, the treatment should be considered long-term.

This opinion is reinforced by pharmaceutical companies, who say that the findings "underscore the persistent character of obesity," similar to managing conditions like diabetes.

Patient Testimonies

Individuals who have come off the medication describe a sudden resurgence of hunger.

"It felt as if a trigger that goes on and you become starving," described a patient.

This difficulty is exacerbated if users have not adopted permanent dietary or behavioural modifications during therapy.

Growing Adoption

Figures show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.

  • Adoption is greater among females compared to men.
  • The 40s and 50s age group shows the greatest usage rates.
  • Many obtain the drugs through private prescriptions rather than the NHS.

Ultimately, researchers caution that while the jabs are effective tools for shedding pounds, they are not a magic fix and long-term success likely depends on integrated behavioural management.

TM
By

Tiffany Mccormick

A seasoned urban analyst and writer, passionate about London's cultural and economic dynamics.

London Stake Source

Type to search articles.